Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Misses on EPS — Stock Down 2.51%

Aurinia Pharmaceuticals reported a loss per share that was worse than expected, leading to a decline in stock price by 2.51%. Investors may be concerned about the lack of revenue figures and guidance, which adds uncertainty to the company's outlook. The absence of management commentary further complicates the interpretation of these results.